Engineered extracellular vesicles-like biomimetic nanoparticles as an emerging platform for targeted cancer therapy

Nanotechnology offers the possibility of revolutionizing cancer theranostics in the new era of precision oncology. Extracellular vesicles (EVs)-like biomimetic nanoparticles (EBPs) have recently emerged as a promising platform for targeted cancer drug delivery. Compared with conventional synthetic v...

Full description

Saved in:
Bibliographic Details
Published inJournal of nanobiotechnology Vol. 21; no. 1; pp. 1 - 30
Main Authors Liu, Xinyi, Xiao, Chunxiu, Xiao, Kai
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 22.08.2023
BioMed Central
BMC
Subjects
Animal models
Antibodies
Anticancer properties
Antineoplastic drugs
Antitumor agents
Biocompatibility
Biomedical engineering
Biomimetic nanoparticles
Biomimetics
Cancer
Cancer therapies
Care and treatment
Cell fusion
Clinical trials
Drug carriers
Drug delivery
Drug delivery system
Drug delivery systems
Drugs
Efficiency
Engineering strategy
Extracellular vesicles
Extracellular vesicles (EVs)
Forecasts and trends
Functionalization
Genetic engineering
Immune system
Immunogenicity
Magnetic fields
Nanomaterials
Nanoparticles
Nanotechnology
Precision medicine
Proteins
Review
Targeted cancer therapy
Technology application
Toxicity
Tumors
Vesicles
China
Online AccessGet full text

Cover

Abstract Nanotechnology offers the possibility of revolutionizing cancer theranostics in the new era of precision oncology. Extracellular vesicles (EVs)-like biomimetic nanoparticles (EBPs) have recently emerged as a promising platform for targeted cancer drug delivery. Compared with conventional synthetic vehicles, EBPs have several advantages, such as lower immunogenicity, longer circulation time, and better targeting capability. Studies on EBPs as cancer therapeutics are rapidly progressing from in vitro experiments to in vivo animal models and early-stage clinical trials. Here, we describe engineering strategies to further improve EBPs as effective anticancer drug carriers, including genetic manipulation of original cells, fusion with synthetic nanomaterials, and direct modification of EVs. These engineering approaches can improve the anticancer performance of EBPs, especially in terms of tumor targeting effectiveness, stealth property, drug loading capacity, and integration with other therapeutic modalities. Finally, the current obstacles and future perspectives of engineered EBPs as the next-generation delivery platform for anticancer drugs are discussed.
AbstractList Nanotechnology offers the possibility of revolutionizing cancer theranostics in the new era of precision oncology. Extracellular vesicles (EVs)-like biomimetic nanoparticles (EBPs) have recently emerged as a promising platform for targeted cancer drug delivery. Compared with conventional synthetic vehicles, EBPs have several advantages, such as lower immunogenicity, longer circulation time, and better targeting capability. Studies on EBPs as cancer therapeutics are rapidly progressing from in vitro experiments to in vivo animal models and early-stage clinical trials. Here, we describe engineering strategies to further improve EBPs as effective anticancer drug carriers, including genetic manipulation of original cells, fusion with synthetic nanomaterials, and direct modification of EVs. These engineering approaches can improve the anticancer performance of EBPs, especially in terms of tumor targeting effectiveness, stealth property, drug loading capacity, and integration with other therapeutic modalities. Finally, the current obstacles and future perspectives of engineered EBPs as the next-generation delivery platform for anticancer drugs are discussed.
Nanotechnology offers the possibility of revolutionizing cancer theranostics in the new era of precision oncology. Extracellular vesicles (EVs)-like biomimetic nanoparticles (EBPs) have recently emerged as a promising platform for targeted cancer drug delivery. Compared with conventional synthetic vehicles, EBPs have several advantages, such as lower immunogenicity, longer circulation time, and better targeting capability. Studies on EBPs as cancer therapeutics are rapidly progressing from in vitro experiments to in vivo animal models and early-stage clinical trials. Here, we describe engineering strategies to further improve EBPs as effective anticancer drug carriers, including genetic manipulation of original cells, fusion with synthetic nanomaterials, and direct modification of EVs. These engineering approaches can improve the anticancer performance of EBPs, especially in terms of tumor targeting effectiveness, stealth property, drug loading capacity, and integration with other therapeutic modalities. Finally, the current obstacles and future perspectives of engineered EBPs as the next-generation delivery platform for anticancer drugs are discussed.Nanotechnology offers the possibility of revolutionizing cancer theranostics in the new era of precision oncology. Extracellular vesicles (EVs)-like biomimetic nanoparticles (EBPs) have recently emerged as a promising platform for targeted cancer drug delivery. Compared with conventional synthetic vehicles, EBPs have several advantages, such as lower immunogenicity, longer circulation time, and better targeting capability. Studies on EBPs as cancer therapeutics are rapidly progressing from in vitro experiments to in vivo animal models and early-stage clinical trials. Here, we describe engineering strategies to further improve EBPs as effective anticancer drug carriers, including genetic manipulation of original cells, fusion with synthetic nanomaterials, and direct modification of EVs. These engineering approaches can improve the anticancer performance of EBPs, especially in terms of tumor targeting effectiveness, stealth property, drug loading capacity, and integration with other therapeutic modalities. Finally, the current obstacles and future perspectives of engineered EBPs as the next-generation delivery platform for anticancer drugs are discussed.
Abstract Nanotechnology offers the possibility of revolutionizing cancer theranostics in the new era of precision oncology. Extracellular vesicles (EVs)-like biomimetic nanoparticles (EBPs) have recently emerged as a promising platform for targeted cancer drug delivery. Compared with conventional synthetic vehicles, EBPs have several advantages, such as lower immunogenicity, longer circulation time, and better targeting capability. Studies on EBPs as cancer therapeutics are rapidly progressing from in vitro experiments to in vivo animal models and early-stage clinical trials. Here, we describe engineering strategies to further improve EBPs as effective anticancer drug carriers, including genetic manipulation of original cells, fusion with synthetic nanomaterials, and direct modification of EVs. These engineering approaches can improve the anticancer performance of EBPs, especially in terms of tumor targeting effectiveness, stealth property, drug loading capacity, and integration with other therapeutic modalities. Finally, the current obstacles and future perspectives of engineered EBPs as the next-generation delivery platform for anticancer drugs are discussed.
Nanotechnology offers the possibility of revolutionizing cancer theranostics in the new era of precision oncology. Extracellular vesicles (EVs)-like biomimetic nanoparticles (EBPs) have recently emerged as a promising platform for targeted cancer drug delivery. Compared with conventional synthetic vehicles, EBPs have several advantages, such as lower immunogenicity, longer circulation time, and better targeting capability. Studies on EBPs as cancer therapeutics are rapidly progressing from in vitro experiments to in vivo animal models and early-stage clinical trials. Here, we describe engineering strategies to further improve EBPs as effective anticancer drug carriers, including genetic manipulation of original cells, fusion with synthetic nanomaterials, and direct modification of EVs. These engineering approaches can improve the anticancer performance of EBPs, especially in terms of tumor targeting effectiveness, stealth property, drug loading capacity, and integration with other therapeutic modalities. Finally, the current obstacles and future perspectives of engineered EBPs as the next-generation delivery platform for anticancer drugs are discussed. Keywords: Extracellular vesicles (EVs), Biomimetic nanoparticles, Drug delivery system, Engineering strategy, Functionalization, Targeted cancer therapy
ArticleNumber 287
Audience Academic
Author Liu, Xinyi
Xiao, Chunxiu
Xiao, Kai
Author_xml – sequence: 1
  givenname: Xinyi
  surname: Liu
  fullname: Liu, Xinyi
– sequence: 2
  givenname: Chunxiu
  surname: Xiao
  fullname: Xiao, Chunxiu
– sequence: 3
  givenname: Kai
  surname: Xiao
  fullname: Xiao, Kai
BookMark eNp9kktv1DAUhSNURNuBP8AqEhtYpPgVO16hqiowUiUkHmvL8dykLok92ElF_z03MyNgKoTycGKf80k-PufFSYgBiuIlJReUNvJtpkzXtCKM40OkqOiT4owKpSpO6_rkr-_T4jznO0IYE0w8K065kqRhujkr8nXofQBIsCnh55Ssg2GYB5vKe8jeDZCrwX-HsvVx9CNM3pXBhri1adqtlhbvUMIICTl9uR3s1MU0lvgqJ5t6mJDsbHCA_7eQ7PbhefG0s0OGF4dxVXx7f_316mN18-nD-urypnK1qqdKb4hiG6s0V8TpFhxw0baqE61yDmqhCDChHTinCZFEUNERqoQmXHOuG81XxXrP3UR7Z7bJjzY9mGi92U3E1JvDNgzimZSypYQLUTeNRpjGEUhHXG0X1rs9azu3I2wcBMxqOIIerwR_a_p4bygRkkvOkPD6QEjxxwx5MqPPS9o2QJyzYU0tOdWCK5S-eiS9i3MKmBWqZC0YnqT8o-ot7sCHLi7Ht0DNpZK0YWQhroqLf6jw2sDoHRaq8zh_ZHhzZEDNhM3o7ZyzWX_5fKxle61LMecE3e9AKDFLR82-owY7anYdNRRNzSOT85OdfFyC88P_rL8A2HbqYQ
CitedBy_id crossref_primary_10_3389_fphar_2024_1438177
crossref_primary_10_1186_s12951_025_03254_9
crossref_primary_10_1186_s12645_024_00284_0
crossref_primary_10_1016_j_jormas_2024_101964
crossref_primary_10_1016_j_dyepig_2025_112699
crossref_primary_10_1016_j_drudis_2024_103991
crossref_primary_10_2174_0113892002323535240830093452
crossref_primary_10_3390_cells13040336
crossref_primary_10_1186_s12951_024_02460_1
crossref_primary_10_1007_s11051_023_05909_w
crossref_primary_10_1016_j_apsb_2025_03_021
crossref_primary_10_3390_nano13243097
crossref_primary_10_1016_j_jddst_2025_106847
crossref_primary_10_1021_acsanm_4c04925
Cites_doi 10.1186/s12951-020-00711-5
10.3390/pharmaceutics14091819
10.1074/jbc.M114.588046
10.3389/fmolb.2021.738219
10.1016/j.jconrel.2019.08.037
10.1016/j.jconrel.2019.12.032
10.1002/mabi.202100042
10.1021/acssensors.9b00418
10.1002/jev2.12198
10.1021/acsnano.7b08199
10.1038/nnano.2007.387
10.2147/IJN.S143264
10.1016/j.biomaterials.2022.121384
10.1002/jev2.12238
10.4049/jimmunol.180.5.3081
10.1039/C4LC00136B
10.7150/thno.59121
10.1002/jev2.12193
10.1021/acs.molpharmaceut.1c00448
10.1021/jacs.8b03584
10.1016/j.jconrel.2019.12.005
10.1021/acsami.0c22883
10.1126/sciadv.abj7002
10.1002/adhm.202101387
10.1126/sciadv.abj8207
10.1021/acs.nanolett.9b03817
10.1002/jev2.12057
10.1016/j.drudis.2014.09.018
10.1016/j.jconrel.2019.11.009
10.2147/IJN.S293067
10.1038/ncb1800
10.1016/j.biomaterials.2018.11.021
10.1016/j.actbio.2021.07.021
10.1021/acsnano.1c05613
10.1038/s41565-022-01098-0
10.7150/thno.62330
10.1016/j.jconrel.2020.12.039
10.1002/adfm.202008326
10.1021/acs.nanolett.0c04122
10.1016/j.addr.2021.113843
10.1186/s12935-021-02157-7
10.1002/adma.202110364
10.3390/cancers6031769
10.1021/acssensors.8b01564
10.1016/j.biomaterials.2018.06.029
10.1016/S1470-2045(20)30073-5
10.1002/adma.202002085
10.2147/IJN.S244849
10.1038/ncb1596
10.1016/j.ymthe.2019.11.020
10.1080/20013078.2020.1806444
10.1002/VIW.20220011
10.1016/j.actbio.2022.05.018
10.1039/C9NR05865F
10.1002/advs.201901293
10.1186/s12951-018-0392-8
10.1016/j.biomaterials.2020.120546
10.1002/anie.201912524
10.3390/cancers13153700
10.1007/s13346-018-0587-4
10.1039/D0NR00523A
10.2147/IJN.S210731
10.3390/cancers11101560
10.1016/j.biomaterials.2019.05.004
10.1021/acsomega.9b04150
10.1038/cr.2017.62
10.1016/j.colsurfb.2021.111915
10.1016/j.carbpol.2018.08.141
10.1038/s41467-020-14963-0
10.1038/s41392-022-00894-3
10.3390/pharmaceutics13101547
10.1016/j.biomaterials.2012.08.072
10.1186/s12951-022-01264-5
10.1002/advs.202000515
10.1080/20013078.2018.1535750
10.1021/acsami.9b11223
10.1002/smll.201903761
10.1186/s12951-021-01189-5
10.1021/acsami.1c10325
10.1039/D1BM00446H
10.1021/acsnano.1c07587
10.1021/jacs.8b10047
10.1016/j.biomaterials.2021.121056
10.1021/acs.nanolett.9b02182
10.1186/s12943-022-01515-x
10.1016/j.biomaterials.2019.01.024
10.1016/j.biomaterials.2021.120964
10.1093/nar/gkaa683
10.1016/j.jconrel.2023.01.057
10.1158/1535-7163.MCT-19-0928
10.1016/j.jconrel.2023.01.073
10.7150/thno.45028
10.1073/pnas.2114006119
10.1038/natrevmats.2016.14
10.1371/journal.pone.0007140
10.1002/adfm.202006515
10.1016/j.actbio.2020.03.030
10.1002/jev2.12187
10.1021/acs.nanolett.8b01236
10.1021/acs.nanolett.9b00824
10.1021/acsnano.8b02587
10.1002/adma.202005562
10.1016/j.biomaterials.2021.121234
10.1016/j.jconrel.2020.03.039
10.1158/0008-5472.CAN-17-2880
10.1039/D1NR08170E
10.1016/j.jcyt.2017.08.004
10.1093/neuonc/noac071
10.1002/adma.201705350
10.1021/acsami.7b18135
10.3389/fmolb.2021.743013
10.1038/s41573-020-0090-8
10.1021/acsnano.1c05505
10.1002/adhm.202101496
10.3390/biomedicines10010130
10.1016/j.jconrel.2019.08.021
10.2174/0929867325666171229141156
10.1038/nbt.3330
10.1093/pcmedi/pbab014
10.1016/j.biomaterials.2022.121424
10.1039/C1NR11297J
10.1186/s12951-019-0563-2
10.1158/1535-7163.MCT-17-0827
10.1016/j.jconrel.2020.07.033
10.2217/nnm-2017-0336
10.3390/pharmaceutics12111079
10.7150/thno.11852
10.3389/fbioe.2020.01010
ContentType Journal Article
Copyright COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2023. BioMed Central Ltd., part of Springer Nature.
BioMed Central Ltd., part of Springer Nature 2023
Copyright_xml – notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2023. BioMed Central Ltd., part of Springer Nature.
– notice: BioMed Central Ltd., part of Springer Nature 2023
DBID AAYXX
CITATION
ISR
3V.
7QO
7TB
7X7
7XB
88E
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABJCF
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
CCPQU
D1I
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
KB.
LK8
M0S
M1P
M7P
P64
PDBOC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12951-023-02064-1
DatabaseName CrossRef
Gale In Context: Science
ProQuest Central (Corporate)
Biotechnology Research Abstracts
Mechanical & Transportation Engineering Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection (ProQuest)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central (New)
Technology Collection
Natural Science Collection
ProQuest One Community College
ProQuest Materials Science Collection
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Materials Science Database
Biological Sciences
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
Biological Science Database
Biotechnology and BioEngineering Abstracts
Materials Science Collection (ProQuest)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest Central Student
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
Mechanical & Transportation Engineering Abstracts
ProQuest Central Essentials
Materials Science Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
Materials Science Database
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Materials Science Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Materials Science & Engineering Collection
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

Publicly Available Content Database

CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
EISSN 1477-3155
EndPage 30
ExternalDocumentID oai_doaj_org_article_9be2666b10344588914f9588e0f0c5a9
PMC10463632
A761820856
10_1186_s12951_023_02064_1
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: ;
  grantid: 2022-GH02-00023-HZ
– fundername: ;
  grantid: ZYJC18026
– fundername: ;
  grantid: 2021ZYD0097
– fundername: ;
  grantid: 2020HXFH023
– fundername: ;
  grantid: 81630101
GroupedDBID ---
0R~
29L
2WC
53G
5VS
7X7
88E
8FE
8FG
8FH
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABJCF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADDVE
ADMLS
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BGLVJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
D1I
DIK
DU5
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
I-F
IAO
IHR
INH
INR
ISR
ITC
ITG
ITH
KB.
KQ8
LK8
M1P
M48
M7P
MM.
M~E
O5R
O5S
OK1
OVT
P2P
PDBOC
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
RVI
SCM
SOJ
SV3
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
PMFND
3V.
7QO
7TB
7XB
8FD
8FK
AZQEC
DWQXO
FR3
GNUQQ
K9.
P64
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c575t-9d072da79370c9bece34bb7f4b7cce5470e249cecc90060414f01749039339893
IEDL.DBID M48
ISSN 1477-3155
IngestDate Wed Aug 27 00:56:19 EDT 2025
Thu Aug 21 18:36:19 EDT 2025
Sun Aug 24 04:03:52 EDT 2025
Fri Jul 25 10:34:25 EDT 2025
Tue Jun 17 21:33:04 EDT 2025
Tue Jun 10 21:19:18 EDT 2025
Fri Jun 27 05:48:47 EDT 2025
Tue Jul 01 01:26:54 EDT 2025
Thu Apr 24 22:53:30 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c575t-9d072da79370c9bece34bb7f4b7cce5470e249cecc90060414f01749039339893
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12951-023-02064-1
PMID 37608298
PQID 2865420026
PQPubID 44676
PageCount 30
ParticipantIDs doaj_primary_oai_doaj_org_article_9be2666b10344588914f9588e0f0c5a9
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10463632
proquest_miscellaneous_2856319437
proquest_journals_2865420026
gale_infotracmisc_A761820856
gale_infotracacademiconefile_A761820856
gale_incontextgauss_ISR_A761820856
crossref_primary_10_1186_s12951_023_02064_1
crossref_citationtrail_10_1186_s12951_023_02064_1
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-08-22
PublicationDateYYYYMMDD 2023-08-22
PublicationDate_xml – month: 08
  year: 2023
  text: 2023-08-22
  day: 22
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Journal of nanobiotechnology
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References P Lara (2064_CR117) 2021; 13
X Song (2064_CR32) 2023; 355
C Feng (2064_CR57) 2021; 6
L Zhang (2064_CR16) 2021; 16
P Guo (2064_CR19) 2021; 31
L Deng (2064_CR89) 2021; 9
K Chen (2064_CR113) 2022; 10
Y Wang (2064_CR31) 2022; 147
TC Pham (2064_CR100) 2021; 10
H Gomari (2064_CR42) 2019; 14
M Xu (2064_CR33) 2021; 11
RJ Bose (2064_CR36) 2022; 11
L Jiang (2064_CR50) 2021; 13
F Xiong (2064_CR67) 2019; 19
L Li (2064_CR108) 2022; 20
A Görgens (2064_CR132) 2022; 11
W Zhou (2064_CR122) 2021; 268
M Zhuang (2064_CR51) 2020; 12
L Huang (2064_CR56) 2022; 21
C Ma (2064_CR124) 2022; 119
Z Yan (2064_CR15) 2019; 4
Q Cheng (2064_CR25) 2018; 140
W Huang (2064_CR55) 2020; 108
WT Shen (2064_CR72) 2021; 21
X Cao (2064_CR85) 2020; 15
R Li (2064_CR101) 2021; 279
JH Wang (2064_CR40) 2018; 17
B Xu (2064_CR24) 2017; 27
J Du (2064_CR34) 2021; 11
J Skog (2064_CR9) 2008; 10
SH Kwon (2064_CR103) 2021; 205
JM Lewis (2064_CR13) 2018; 12
S Tan (2064_CR18) 2015; 5
D Wang (2064_CR78) 2020; 7
L Guo (2064_CR92) 2007; 34
TG Nguyen Cao (2064_CR104) 2021; 13
T Tian (2064_CR91) 2022; 16
J Wang (2064_CR120) 2021; 276
S Cavallaro (2064_CR14) 2019; 4
L Wang (2064_CR39) 2020; 18
Y Cao (2064_CR80) 2019; 13
T Tian (2064_CR23) 2014; 289
B Lorenzini (2064_CR131) 2023; 355
H Valadi (2064_CR12) 2007; 9
Y Shi (2064_CR49) 2021; 19
Y Chen (2064_CR52) 2022; 9
Q Zhan (2064_CR98) 2022; 24
S Kamerkar (2064_CR58) 2022; 8
J Zhuang (2064_CR97) 2020; 48
MS de Guimarães (2064_CR96) 2022; 14
D Pandita (2064_CR129) 2015; 20
G Wang (2064_CR74) 2019; 11
G Cheng (2064_CR81) 2018; 140
P Zhupanyn (2064_CR76) 2020; 319
R Kandimalla (2064_CR17) 2021; 13
Q Jiang (2064_CR86) 2019; 192
AV Forterre (2064_CR110) 2020; 19
Z Belhadj (2064_CR123) 2020; 9
J Ding (2064_CR116) 2021; 33
Q Guo (2064_CR125) 2021; 15
A Can (2064_CR130) 2017; 19
H Liu (2064_CR26) 2020; 30
YN Tan (2064_CR90) 2022; 11
S Wilhelm (2064_CR5) 2016; 1
S Song (2064_CR11) 2023; 4(2)
D Zhang (2064_CR70) 2019; 197
C Théry (2064_CR7) 2018; 7
X Shi (2064_CR38) 2020; 28
Z Ye (2064_CR107) 2018; 10
YK Gong (2064_CR21) 2012; 4
G Ma (2064_CR44) 2021; 134
L Zhao (2064_CR68) 2020; 318
MJ Mitchell (2064_CR65) 2021; 20
Y Liu (2064_CR64) 2019; 11
K El-Boubbou (2064_CR61) 2018; 13
Z Zheng (2064_CR102) 2019; 311–312
D Nie (2064_CR83) 2020; 20
Z Fan (2064_CR127) 2019; 15
A Montecalvo (2064_CR8) 2008; 180
X Wang (2064_CR115) 2022; 7
T Yong (2064_CR6) 2020; 322
Q Lin (2064_CR93) 2019; 311–312
Q Lv (2064_CR35) 2020; 7
H Cao (2064_CR106) 2018; 18
Q Zhan (2064_CR118) 2020; 10
W Liu (2064_CR29) 2021; 4
S Xu (2064_CR46) 2022; 14
L Cheng (2064_CR27) 2021; 275
M Fan (2064_CR112) 2022; 282
Q Chen (2064_CR75) 2020; 20
T Wu (2064_CR84) 2022; 34
JK Patra (2064_CR4) 2018; 16
E Blanco (2064_CR60) 2015; 33
H Lee (2064_CR126) 2018; 202
S Mahati (2064_CR37) 2021; 8
RJC Bose (2064_CR71) 2018; 12
M Sedighi (2064_CR66) 2019; 9
D Peer (2064_CR3) 2007; 2
Q Xu (2064_CR30) 2020; 326
SS Kanwar (2064_CR22) 2014; 14
R Tian (2064_CR82) 2020; 8
C Luo (2064_CR119) 2019; 11
W Wei (2064_CR1) 2020; 21
A Sarkar (2064_CR10) 2009; 4
J Zhang (2064_CR121) 2022; 8
G Liang (2064_CR43) 2020; 18
Q Zhou (2064_CR109) 2021; 18
S Qing (2064_CR28) 2020; 32
M Sancho-Albero (2064_CR79) 2022; 11
S Han (2064_CR48) 2021; 8
B Peng (2064_CR99) 2022; 11
Q Zhan (2064_CR128) 2021; 21
K Wang (2064_CR45) 2021; 15
S Wang (2064_CR54) 2017; 12
J Wang (2064_CR62) 2020; 5
W Nie (2064_CR94) 2020; 59
M Li (2064_CR69) 2020; 11
A Grangier (2064_CR133) 2021; 176
G Housman (2064_CR2) 2014; 6
G Kim (2064_CR47) 2020; 317
S Bayda (2064_CR63) 2018; 25
G Jia (2064_CR73) 2018; 178
Y Jang (2064_CR114) 2021; 330
W Zhou (2064_CR59) 2021; 21
Y Wan (2064_CR20) 2018; 78
H Cheng (2064_CR105) 2019; 211
P Zhang (2064_CR41) 2018; 30
S Li (2064_CR77) 2020; 12
C Liu (2064_CR53) 2022; 17
Y Ma (2064_CR87) 2022; 282
X Zhou (2064_CR88) 2022; 11
H Wu (2064_CR95) 2013; 34
Y Si (2064_CR111) 2020; 12
References_xml – volume: 18
  start-page: 153
  issue: 1
  year: 2020
  ident: 2064_CR39
  publication-title: J Nanobiotechnology
  doi: 10.1186/s12951-020-00711-5
– volume: 14
  start-page: 1819
  issue: 9
  year: 2022
  ident: 2064_CR96
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics14091819
– volume: 289
  start-page: 22258
  issue: 32
  year: 2014
  ident: 2064_CR23
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M114.588046
– volume: 8
  start-page: 738219
  year: 2021
  ident: 2064_CR37
  publication-title: Front Mol Biosci
  doi: 10.3389/fmolb.2021.738219
– volume: 311–312
  start-page: 104
  year: 2019
  ident: 2064_CR93
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2019.08.037
– volume: 319
  start-page: 63
  year: 2020
  ident: 2064_CR76
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2019.12.032
– volume: 21
  start-page: e2100042
  issue: 8
  year: 2021
  ident: 2064_CR128
  publication-title: Macromol Biosci
  doi: 10.1002/mabi.202100042
– volume: 4
  start-page: 1399
  issue: 5
  year: 2019
  ident: 2064_CR14
  publication-title: ACS Sens
  doi: 10.1021/acssensors.9b00418
– volume: 11
  start-page: e12198
  issue: 3
  year: 2022
  ident: 2064_CR88
  publication-title: J Extracell Vesicles
  doi: 10.1002/jev2.12198
– volume: 12
  start-page: 3311
  issue: 4
  year: 2018
  ident: 2064_CR13
  publication-title: ACS Nano
  doi: 10.1021/acsnano.7b08199
– volume: 2
  start-page: 751
  issue: 12
  year: 2007
  ident: 2064_CR3
  publication-title: Nat Nanotechnol
  doi: 10.1038/nnano.2007.387
– volume: 12
  start-page: 6813
  year: 2017
  ident: 2064_CR54
  publication-title: Int J Nanomed
  doi: 10.2147/IJN.S143264
– volume: 11
  start-page: 100
  issue: 1
  year: 2019
  ident: 2064_CR64
  publication-title: Nanomicro Lett
– volume: 282
  start-page: 121384
  year: 2022
  ident: 2064_CR87
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2022.121384
– volume: 11
  start-page: e12238
  issue: 6
  year: 2022
  ident: 2064_CR132
  publication-title: J Extracell Vesicles
  doi: 10.1002/jev2.12238
– volume: 180
  start-page: 3081
  issue: 5
  year: 2008
  ident: 2064_CR8
  publication-title: J Immunol
  doi: 10.4049/jimmunol.180.5.3081
– volume: 14
  start-page: 1891
  issue: 11
  year: 2014
  ident: 2064_CR22
  publication-title: Lab Chip
  doi: 10.1039/C4LC00136B
– volume: 11
  start-page: 8185
  issue: 17
  year: 2021
  ident: 2064_CR34
  publication-title: Theranostics
  doi: 10.7150/thno.59121
– volume: 11
  start-page: e12193
  issue: 3
  year: 2022
  ident: 2064_CR79
  publication-title: J Extracell Vesicles
  doi: 10.1002/jev2.12193
– volume: 6
  start-page: 963
  issue: 4
  year: 2021
  ident: 2064_CR57
  publication-title: Bioact Mater
– volume: 18
  start-page: 4015
  issue: 11
  year: 2021
  ident: 2064_CR109
  publication-title: Mol Pharm
  doi: 10.1021/acs.molpharmaceut.1c00448
– volume: 140
  start-page: 7282
  issue: 23
  year: 2018
  ident: 2064_CR81
  publication-title: J Am Chem Soc
  doi: 10.1021/jacs.8b03584
– volume: 318
  start-page: 1
  year: 2020
  ident: 2064_CR68
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2019.12.005
– volume: 13
  start-page: 25575
  issue: 22
  year: 2021
  ident: 2064_CR104
  publication-title: ACS Appl Mater Interfaces
  doi: 10.1021/acsami.0c22883
– volume: 8
  start-page: eabj7002
  issue: 7
  year: 2022
  ident: 2064_CR58
  publication-title: Sci Adv
  doi: 10.1126/sciadv.abj7002
– volume: 11
  start-page: e2101387
  issue: 5
  year: 2022
  ident: 2064_CR36
  publication-title: Adv Healthc Mater
  doi: 10.1002/adhm.202101387
– volume: 8
  start-page: eabj8207
  issue: 2
  year: 2022
  ident: 2064_CR121
  publication-title: Sci Adv
  doi: 10.1126/sciadv.abj8207
– volume: 20
  start-page: 936
  issue: 2
  year: 2020
  ident: 2064_CR83
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.9b03817
– volume: 10
  start-page: e12057
  issue: 4
  year: 2021
  ident: 2064_CR100
  publication-title: J Extracell Vesicles
  doi: 10.1002/jev2.12057
– volume: 20
  start-page: 95
  issue: 1
  year: 2015
  ident: 2064_CR129
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2014.09.018
– volume: 317
  start-page: 273
  year: 2020
  ident: 2064_CR47
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2019.11.009
– volume: 16
  start-page: 1575
  year: 2021
  ident: 2064_CR16
  publication-title: Int J Nanomed
  doi: 10.2147/IJN.S293067
– volume: 13
  start-page: 1499
  issue: 2
  year: 2019
  ident: 2064_CR80
  publication-title: ACS Nano
– volume: 10
  start-page: 1470
  issue: 12
  year: 2008
  ident: 2064_CR9
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb1800
– volume: 192
  start-page: 292
  year: 2019
  ident: 2064_CR86
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2018.11.021
– volume: 134
  start-page: 559
  year: 2021
  ident: 2064_CR44
  publication-title: Acta Biomater
  doi: 10.1016/j.actbio.2021.07.021
– volume: 15
  start-page: 13826
  issue: 8
  year: 2021
  ident: 2064_CR125
  publication-title: ACS Nano
  doi: 10.1021/acsnano.1c05613
– volume: 17
  start-page: 531
  issue: 5
  year: 2022
  ident: 2064_CR53
  publication-title: Nat Nanotechnol
  doi: 10.1038/s41565-022-01098-0
– volume: 11
  start-page: 8926
  issue: 18
  year: 2021
  ident: 2064_CR33
  publication-title: Theranostics
  doi: 10.7150/thno.62330
– volume: 330
  start-page: 293
  year: 2021
  ident: 2064_CR114
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2020.12.039
– volume: 31
  start-page: 2008326
  issue: 44
  year: 2021
  ident: 2064_CR19
  publication-title: Adv Funct Mater
  doi: 10.1002/adfm.202008326
– volume: 21
  start-page: 1375
  issue: 3
  year: 2021
  ident: 2064_CR72
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.0c04122
– volume: 176
  start-page: 113843
  year: 2021
  ident: 2064_CR133
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2021.113843
– volume: 21
  start-page: 485
  issue: 1
  year: 2021
  ident: 2064_CR59
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-021-02157-7
– volume: 34
  start-page: e2110364
  issue: 15
  year: 2022
  ident: 2064_CR84
  publication-title: Adv Mater
  doi: 10.1002/adma.202110364
– volume: 6
  start-page: 1769
  issue: 3
  year: 2014
  ident: 2064_CR2
  publication-title: Cancers
  doi: 10.3390/cancers6031769
– volume: 4
  start-page: 488
  issue: 2
  year: 2019
  ident: 2064_CR15
  publication-title: ACS Sens
  doi: 10.1021/acssensors.8b01564
– volume: 178
  start-page: 302
  year: 2018
  ident: 2064_CR73
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2018.06.029
– volume: 21
  start-page: e342
  issue: 7
  year: 2020
  ident: 2064_CR1
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(20)30073-5
– volume: 32
  start-page: 2002085
  issue: 47
  year: 2020
  ident: 2064_CR28
  publication-title: Adv Mater
  doi: 10.1002/adma.202002085
– volume: 15
  start-page: 1915
  year: 2020
  ident: 2064_CR85
  publication-title: Int J Nanomedicine
  doi: 10.2147/IJN.S244849
– volume: 9
  start-page: 654
  issue: 6
  year: 2007
  ident: 2064_CR12
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb1596
– volume: 28
  start-page: 536
  issue: 2
  year: 2020
  ident: 2064_CR38
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2019.11.020
– volume: 9
  start-page: 1806444
  issue: 1
  year: 2020
  ident: 2064_CR123
  publication-title: J Extracell Vesicles
  doi: 10.1080/20013078.2020.1806444
– volume: 4(2)
  start-page: 20220011
  year: 2023
  ident: 2064_CR11
  publication-title: VIEW
  doi: 10.1002/VIW.20220011
– volume: 147
  start-page: 342
  year: 2022
  ident: 2064_CR31
  publication-title: Acta Biomater
  doi: 10.1016/j.actbio.2022.05.018
– volume: 12
  start-page: 173
  issue: 1
  year: 2020
  ident: 2064_CR51
  publication-title: Nanoscale
  doi: 10.1039/C9NR05865F
– volume: 7
  start-page: 1901293
  issue: 3
  year: 2020
  ident: 2064_CR78
  publication-title: Adv Sci
  doi: 10.1002/advs.201901293
– volume: 16
  start-page: 71
  issue: 1
  year: 2018
  ident: 2064_CR4
  publication-title: J Nanobiotechnol
  doi: 10.1186/s12951-018-0392-8
– volume: 268
  start-page: 120546
  year: 2021
  ident: 2064_CR122
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2020.120546
– volume: 59
  start-page: 2018
  issue: 5
  year: 2020
  ident: 2064_CR94
  publication-title: Angew Chem Int Ed Engl
  doi: 10.1002/anie.201912524
– volume: 13
  start-page: 3700
  issue: 15
  year: 2021
  ident: 2064_CR17
  publication-title: Cancers
  doi: 10.3390/cancers13153700
– volume: 9
  start-page: 404
  issue: 1
  year: 2019
  ident: 2064_CR66
  publication-title: Drug Deliv Transl Res
  doi: 10.1007/s13346-018-0587-4
– volume: 12
  start-page: 10854
  issue: 19
  year: 2020
  ident: 2064_CR77
  publication-title: Nanoscale
  doi: 10.1039/D0NR00523A
– volume: 14
  start-page: 5679
  year: 2019
  ident: 2064_CR42
  publication-title: Int J Nanomed
  doi: 10.2147/IJN.S210731
– volume: 11
  start-page: 1560
  issue: 10
  year: 2019
  ident: 2064_CR74
  publication-title: Cancers
  doi: 10.3390/cancers11101560
– volume: 34
  start-page: 1080
  year: 2007
  ident: 2064_CR92
  publication-title: Progress Biochem Biophys
– volume: 211
  start-page: 14
  year: 2019
  ident: 2064_CR105
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2019.05.004
– volume: 5
  start-page: 926
  issue: 1
  year: 2020
  ident: 2064_CR62
  publication-title: ACS Omega
  doi: 10.1021/acsomega.9b04150
– volume: 27
  start-page: 882
  issue: 7
  year: 2017
  ident: 2064_CR24
  publication-title: Cell Res
  doi: 10.1038/cr.2017.62
– volume: 205
  start-page: 111915
  year: 2021
  ident: 2064_CR103
  publication-title: Colloids Surf B Biointerfaces
  doi: 10.1016/j.colsurfb.2021.111915
– volume: 202
  start-page: 323
  year: 2018
  ident: 2064_CR126
  publication-title: Carbohydr Polym
  doi: 10.1016/j.carbpol.2018.08.141
– volume: 11
  start-page: 1126
  issue: 1
  year: 2020
  ident: 2064_CR69
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-14963-0
– volume: 7
  start-page: 74
  issue: 1
  year: 2022
  ident: 2064_CR115
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-022-00894-3
– volume: 13
  start-page: 1547
  issue: 10
  year: 2021
  ident: 2064_CR117
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics13101547
– volume: 34
  start-page: 1213
  issue: 4
  year: 2013
  ident: 2064_CR95
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2012.08.072
– volume: 20
  start-page: 50
  issue: 1
  year: 2022
  ident: 2064_CR108
  publication-title: J Nanobiotechnol
  doi: 10.1186/s12951-022-01264-5
– volume: 7
  start-page: 2000515
  issue: 18
  year: 2020
  ident: 2064_CR35
  publication-title: Adv Sci
  doi: 10.1002/advs.202000515
– volume: 7
  start-page: 1535750
  issue: 1
  year: 2018
  ident: 2064_CR7
  publication-title: J Extracell Vesicles
  doi: 10.1080/20013078.2018.1535750
– volume: 11
  start-page: 43811
  issue: 47
  year: 2019
  ident: 2064_CR119
  publication-title: ACS Appl Mater Interfaces
  doi: 10.1021/acsami.9b11223
– volume: 15
  start-page: e1903761
  issue: 47
  year: 2019
  ident: 2064_CR127
  publication-title: Small
  doi: 10.1002/smll.201903761
– volume: 19
  start-page: 447
  issue: 1
  year: 2021
  ident: 2064_CR49
  publication-title: J Nanobiotechnology
  doi: 10.1186/s12951-021-01189-5
– volume: 13
  start-page: 42411
  issue: 36
  year: 2021
  ident: 2064_CR50
  publication-title: ACS Appl Mater Interfaces
  doi: 10.1021/acsami.1c10325
– volume: 9
  start-page: 251
  year: 2022
  ident: 2064_CR52
  publication-title: Bioact Mater
– volume: 9
  start-page: 5599
  issue: 16
  year: 2021
  ident: 2064_CR89
  publication-title: Biomater Sci
  doi: 10.1039/D1BM00446H
– volume: 15
  start-page: 18327
  issue: 11
  year: 2021
  ident: 2064_CR45
  publication-title: ACS Nano
  doi: 10.1021/acsnano.1c07587
– volume: 140
  start-page: 16413
  issue: 48
  year: 2018
  ident: 2064_CR25
  publication-title: J Am Chem Soc
  doi: 10.1021/jacs.8b10047
– volume: 276
  start-page: 121056
  year: 2021
  ident: 2064_CR120
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2021.121056
– volume: 20
  start-page: 11
  issue: 1
  year: 2020
  ident: 2064_CR75
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.9b02182
– volume: 21
  start-page: 45
  issue: 1
  year: 2022
  ident: 2064_CR56
  publication-title: Mol Cancer
  doi: 10.1186/s12943-022-01515-x
– volume: 197
  start-page: 220
  year: 2019
  ident: 2064_CR70
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2019.01.024
– volume: 275
  start-page: 120964
  year: 2021
  ident: 2064_CR27
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2021.120964
– volume: 48
  start-page: 8870
  issue: 16
  year: 2020
  ident: 2064_CR97
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkaa683
– volume: 355
  start-page: 18
  year: 2023
  ident: 2064_CR32
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2023.01.057
– volume: 19
  start-page: 858
  issue: 3
  year: 2020
  ident: 2064_CR110
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-19-0928
– volume: 355
  start-page: 501
  year: 2023
  ident: 2064_CR131
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2023.01.073
– volume: 10
  start-page: 7889
  issue: 17
  year: 2020
  ident: 2064_CR118
  publication-title: Theranostics
  doi: 10.7150/thno.45028
– volume: 119
  start-page: e2114006119
  issue: 6
  year: 2022
  ident: 2064_CR124
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.2114006119
– volume: 1
  start-page: 16014
  issue: 5
  year: 2016
  ident: 2064_CR5
  publication-title: Nat Rev Mater
  doi: 10.1038/natrevmats.2016.14
– volume: 4
  start-page: e7140
  issue: 9
  year: 2009
  ident: 2064_CR10
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0007140
– volume: 30
  start-page: 2006515
  issue: 52
  year: 2020
  ident: 2064_CR26
  publication-title: Adv Func Mater
  doi: 10.1002/adfm.202006515
– volume: 108
  start-page: 300
  year: 2020
  ident: 2064_CR55
  publication-title: Acta Biomater
  doi: 10.1016/j.actbio.2020.03.030
– volume: 11
  start-page: e12187
  issue: 4
  year: 2022
  ident: 2064_CR99
  publication-title: J Extracell Vesicles
  doi: 10.1002/jev2.12187
– volume: 18
  start-page: 4762
  issue: 8
  year: 2018
  ident: 2064_CR106
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.8b01236
– volume: 19
  start-page: 3256
  issue: 5
  year: 2019
  ident: 2064_CR67
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.9b00824
– volume: 12
  start-page: 10817
  issue: 11
  year: 2018
  ident: 2064_CR71
  publication-title: ACS Nano
  doi: 10.1021/acsnano.8b02587
– volume: 33
  start-page: e2005562
  issue: 7
  year: 2021
  ident: 2064_CR116
  publication-title: Adv Mater
  doi: 10.1002/adma.202005562
– volume: 279
  start-page: 121234
  year: 2021
  ident: 2064_CR101
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2021.121234
– volume: 322
  start-page: 555
  year: 2020
  ident: 2064_CR6
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2020.03.039
– volume: 78
  start-page: 798
  issue: 3
  year: 2018
  ident: 2064_CR20
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-17-2880
– volume: 14
  start-page: 4098
  issue: 11
  year: 2022
  ident: 2064_CR46
  publication-title: Nanoscale
  doi: 10.1039/D1NR08170E
– volume: 19
  start-page: 1351
  issue: 12
  year: 2017
  ident: 2064_CR130
  publication-title: Cytotherapy
  doi: 10.1016/j.jcyt.2017.08.004
– volume: 24
  start-page: 1871
  issue: 11
  year: 2022
  ident: 2064_CR98
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/noac071
– volume: 30
  start-page: 1705350
  issue: 7
  year: 2018
  ident: 2064_CR41
  publication-title: Adv Mater
  doi: 10.1002/adma.201705350
– volume: 10
  start-page: 12341
  issue: 15
  year: 2018
  ident: 2064_CR107
  publication-title: ACS Appl Mater Interfaces
  doi: 10.1021/acsami.7b18135
– volume: 8
  start-page: 743013
  year: 2021
  ident: 2064_CR48
  publication-title: Front Mol Biosci
  doi: 10.3389/fmolb.2021.743013
– volume: 20
  start-page: 101
  issue: 2
  year: 2021
  ident: 2064_CR65
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-020-0090-8
– volume: 16
  start-page: 1940
  issue: 2
  year: 2022
  ident: 2064_CR91
  publication-title: ACS Nano
  doi: 10.1021/acsnano.1c05505
– volume: 11
  start-page: e2101496
  issue: 6
  year: 2022
  ident: 2064_CR90
  publication-title: Adv Healthc Mater
  doi: 10.1002/adhm.202101496
– volume: 10
  start-page: 130
  issue: 1
  year: 2022
  ident: 2064_CR113
  publication-title: Biomedicines
  doi: 10.3390/biomedicines10010130
– volume: 311–312
  start-page: 43
  year: 2019
  ident: 2064_CR102
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2019.08.021
– volume: 25
  start-page: 4269
  issue: 34
  year: 2018
  ident: 2064_CR63
  publication-title: Curr Med Chem
  doi: 10.2174/0929867325666171229141156
– volume: 33
  start-page: 941
  issue: 9
  year: 2015
  ident: 2064_CR60
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.3330
– volume: 4
  start-page: 179
  issue: 3
  year: 2021
  ident: 2064_CR29
  publication-title: Precis Clin Med
  doi: 10.1093/pcmedi/pbab014
– volume: 282
  start-page: 121424
  year: 2022
  ident: 2064_CR112
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2022.121424
– volume: 4
  start-page: 360
  issue: 2
  year: 2012
  ident: 2064_CR21
  publication-title: Nanoscale
  doi: 10.1039/C1NR11297J
– volume: 18
  start-page: 10
  issue: 1
  year: 2020
  ident: 2064_CR43
  publication-title: J Nanobiotechnology
  doi: 10.1186/s12951-019-0563-2
– volume: 17
  start-page: 1133
  issue: 5
  year: 2018
  ident: 2064_CR40
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-17-0827
– volume: 326
  start-page: 455
  year: 2020
  ident: 2064_CR30
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2020.07.033
– volume: 13
  start-page: 953
  issue: 8
  year: 2018
  ident: 2064_CR61
  publication-title: Nanomedicine
  doi: 10.2217/nnm-2017-0336
– volume: 12
  start-page: 1079
  issue: 11
  year: 2020
  ident: 2064_CR111
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics12111079
– volume: 5
  start-page: 863
  issue: 8
  year: 2015
  ident: 2064_CR18
  publication-title: Theranostics
  doi: 10.7150/thno.11852
– volume: 8
  start-page: 1010
  year: 2020
  ident: 2064_CR82
  publication-title: Front Bioeng Biotechnol
  doi: 10.3389/fbioe.2020.01010
SSID ssj0022424
Score 2.4429362
SecondaryResourceType review_article
Snippet Nanotechnology offers the possibility of revolutionizing cancer theranostics in the new era of precision oncology. Extracellular vesicles (EVs)-like biomimetic...
Abstract Nanotechnology offers the possibility of revolutionizing cancer theranostics in the new era of precision oncology. Extracellular vesicles (EVs)-like...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1
SubjectTerms Animal models
Antibodies
Anticancer properties
Antineoplastic drugs
Antitumor agents
Biocompatibility
Biomedical engineering
Biomimetic nanoparticles
Biomimetics
Cancer
Cancer therapies
Care and treatment
Cell fusion
Clinical trials
Drug carriers
Drug delivery
Drug delivery system
Drug delivery systems
Drugs
Efficiency
Engineering strategy
Extracellular vesicles
Extracellular vesicles (EVs)
Forecasts and trends
Functionalization
Genetic engineering
Immune system
Immunogenicity
Magnetic fields
Nanomaterials
Nanoparticles
Nanotechnology
Precision medicine
Proteins
Review
Targeted cancer therapy
Technology application
Toxicity
Tumors
Vesicles
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dixMxEA9yT_ogfmL1TqIIPshy-5HPxzvxOAV9UA_uLSTZRIu99Lht_fudyWZLV0FfhLIlm8nSzkzmo535hZBXgjnLvPSVU76rWFBdZbsahpq5GGUIUWCj8MdP4vyCfbjkl3tHfWFN2AgPPDLuWLsAPkS4BrHpuFK6YVHDe6hj7bnNrXvg86ZkqqRa2PQwtcgocTyAV-OQNrf4nyU44aqZuaGM1v-nTf69TnLP8ZzdI3dLxEhPxk96n9wK6QG5s4cj-JAM0yj0FIztjcWf47G-lP4MQ657q1bLH4Fir_3yCtsWabIJ0uVSFUctvBLFXmE8s4her-wGg1kKFzrWisOTPSoIjEccgkfk4uzd17fnVTlNofIQkm0q3dey7S3i4dUeuOpDx5yTkTnpfeBM1gFSMQ8i1QjSwoDPsFuZxubdTkNY85gcpHUKTwjFINHBAqGiYCLWVvVRR877VgnpeLMgzcRc4wvUOJ54sTI55VDCjAIxIBCTBWJgzZvdmusRaOOv1Kcosx0lgmTnG6A6pjDP_Et1FuQlStwgDEbCOptvdjsM5v2Xz-ZECkS2V1wsyOtCFNcoP1vaFoATiJw1ozycUcI-9fPpSbFMsRODwb5ghnUyMP1iN40rsfYthfUWabgAQ8k6uSBqppCzrz-fScvvGSu8yYhwXfv0fzDsGbnd5j0ExrU9JAebm204gphs457n7fcLn3EyxQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Technology Collection
  dbid: 8FG
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dixMxEA96vuiD-Imrp0QRfJDl9iPJJk9yivUU9EE9uLeQZJO7Yt2t3da_35lstt4qHJSWNJOWZJL5yM78hpCXglnDXONyK12dMy_r3NQFNBWzITTeB4GJwp-_iJNT9umMn6ULtyGFVU4yMQrqtnd4R36EGZQMIwrEm_WvHKtG4dPVVELjOrlRgqbBkC65-LB3uDD1YUqUkeJoAN3GwXmu8MklqOK8nCmjiNn_v2T-N1rykvpZ3CG3k91Ij0dG3yXXfHeP3LqEJnifDFPLtxRE7sbgpTxGmdLffojRb_lq-cNTzLhf_sTkRdqZDpzmFBtHDbw6ihnDWLmIrldmiyYthTc6RozDLzvcJtAe0QgekNPF--_vTvJUUyF3YJhtc9UWTdUaRMUrnAIG-ppZ2wRmG-c8Z03hwSFzwFiFUC2sZAHOLFOYwlsrMG4ekoOu7_wjQtFUtDBAyCCYCIWRbVCB8xZY1VheZqScFle7BDiOdS9WOjoeUuiRIRoYoiNDNIx5vR-zHuE2rqR-izzbUyJUdvyi35zrtHgaJglbQ9gSwQ25lAqmpODTF6Fw3KiMvECOawTD6DDa5tzshkF__PZVHzcC8e0lFxl5lYhCj_wzKXkBVgLxs2aUhzNKOK1u3j1tLJ2kxaD_7u2MPN9340iMgOt8v0MaLkBcsrrJiJxtyNn05z3d8iIihpcRF66uHl_970_IzSqeDhCe1SE52G52_inYXFv7LB6sP75UK3c
  priority: 102
  providerName: ProQuest
Title Engineered extracellular vesicles-like biomimetic nanoparticles as an emerging platform for targeted cancer therapy
URI https://www.proquest.com/docview/2865420026
https://www.proquest.com/docview/2856319437
https://pubmed.ncbi.nlm.nih.gov/PMC10463632
https://doaj.org/article/9be2666b10344588914f9588e0f0c5a9
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELfG9gIPiE9RGJVBSDygQD78lQeENrQykDahQaW-WbZjj4qSjqZF8N9z5yTVAtOkKpXru1T2-ey75O53hLwQzBrmpEusckXCvCoSU6TQLJkNQXofBCYKn5yK4yn7NOOzHdKXO-omsLnStcN6UtPV4vXvn3_egcK_jQqvxJsGziwOTnGObyThiE3AG9qDk0liRYMTtn2rkGMqRJ84cyXf4HCKGP7_79T_Rk9eOo4md8jtzo6kB63g75IdX98jty6hC94nTd_yFYUteGXwIT1GndJfvonRcMli_t1TzMCf_8BkRlqbGpzoLlaOGvjUFDOIsZIRvViYNZq4FC60jSCHOztcNtBu0QkekOnk6Ov746SrsZA4MNTWSVmlMq8MouSlrgSB-oJZKwOz0jnPmUw9OGgOBF0idAvLWAAdZiWm9BYlGDsPyW69rP0jQtF0tMAgVBBMhNSoKpSB8ypXQlqejUjWT652HQA51sFY6OiIKKFbgWgQiI4C0cDzastz0cJvXEt9iDLbUiJ0dvxhuTrX3eRpGCQYJcJmCHbIlSphSCV8-zSkjptyRJ6jxDWCY9QYfXNuNk2jP3450wdSIN694mJEXnZEYYnyM10yA8wE4mkNKPcHlKC9btjdLyzdL36N2cIMo2eg-9m2GzkxIq72yw3ScAHbJyvkiKjBghwMf9hTz79FBPEs4sQV-ePr__0JuZlH7YDNNN8nu-vVxj8FG2xtx-SGnEm4qsmHMdk7PDr9fDaOzzPGUeX-AihpMvw
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELaqcgAOiKdYWsAgEAe06j68XvuAUHmEhD4O0Eq9Gdtrl6hhN2QTEH-K38jMPkIXpN4qRYkcjzeyZzyeiWe-IeQZZ0Yzm9vQCJuGzIk01GkETcmM97lznmOi8MEhHx-zjyfZyQb53efCYFhlrxMbRV1UFv8j38EMSoYRBfz1_HuIVaPwdrUvodGKxZ779RNctvrV5B3w93mSjN4fvR2HXVWB0IJpsgxlEeVJoREXLrISpuBSZkzumcmtdRnLIwcuiYWpSQQrYTHzILVMYhJrKgWCL4HKv8Kggc6eGH1YO3iYatEn5gi-U8NZmoGznuBNKRz9YTw4_JoaAf-fBP9GZ5477kY3yY3OTqW7rWDdIhuuvE2un0MvvEPqvuUKCip-ofESAKNa6Q9XN9F24Wx65ihm-E-_YbIkLXUJTnoXi0c1vEqKGcpYKYnOZ3qJJjSFN9pGqMOTLYoltFv0g7vk-FJW-x7ZLKvS3ScUTVMDA7jwnHEfaVF46bOsANHITRYHJO4XV9kO4BzrbMxU4-gIrlqGKGCIahiiYMzL9Zh5C-9xIfUb5NmaEqG5my-qxanqFk_BJMHo4SZGMMVMCAlTkvDpIh_ZTMuAPEWOKwTfKDG651Sv6lpNPn9SuzlHPH2R8YC86Ih8hfzTXbIErATidQ0otweUoB3ssLsXLNVpp1r93UsBebLuxpEYcVe6aoU0GQf1zNI8IGIgkIPpD3vK6dcGoTxucOjS5MHFv_6YXB0fHeyr_cnh3ha5ljQ7BRR3sk02l4uVewj23tI8ajYZJV8ue1f_Ad0KZyU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Engineered+extracellular+vesicles-like+biomimetic+nanoparticles+as+an+emerging+platform+for+targeted+cancer+therapy&rft.jtitle=Journal+of+nanobiotechnology&rft.au=Liu%2C+Xinyi&rft.au=Xiao%2C+Chunxiu&rft.au=Xiao%2C+Kai&rft.date=2023-08-22&rft.pub=BioMed+Central&rft.eissn=1477-3155&rft.volume=21&rft.spage=1&rft_id=info:doi/10.1186%2Fs12951-023-02064-1
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-3155&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-3155&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-3155&client=summon